Dr Hjalmar Flygt (Uppsala University Hospital, Sweden) presented data extracted from the Swedish CML registry about patients stopping TKI therapy outside of clinical trials in chronic phase CML [1]. Studies have shown that 40-50% of patients with a deep molecular response (DMR, defined as MR4.0 or lower) successfully remained TKI treatment-free. In the current Swedish Guidelines for CML, stopping TKI therapy can be considered in patients treated with a TKI ≥5 years and an MR4.0 or lower for at least 2 years.
CML patients diagnosed between 2007-2012 (n=584) were analysed, of whom 234 of the 548 evaluable patients (43%) had stopped treatment with TKI ≥1 month. Most interrupted TKI therapy because they had achieved durable MR (56%); other reasons included adverse events (18%), or stem cell transplantation (13%).
In an analysis aimed at determining outcomes of patients treated outside of a clinical trial setting, Dr Flygt pointed out that 29% stopped while enrolled in a clinical trial, whereas 70% stopped their TKI therapy outside a study setting. Median time from diagnosis to TKI stop while in a study was 4.2 years (IQR: 3.6-5.2), and 6.0 years (IQR: 4.0-7.5) for those not enrolled in a study. In total, 48.9% patients had re-initiated TKI treatment at a median of 0.4 years (IQR 0.3-0.6) after stopping TKI. Of those stopping TKI outside a study setting, the probability of remaining TKI treatment-free at 22 months was 61%.
- Flygt H, et al. High level of successful TKI discontinuation outside clinical trials - a population-based study from the Swedish CML registry. EHA25 Virtual, 11-21 June 2020, Abstract S174.
Posted on
Previous Article
« Patients with lower-risk MDS benefit from imetelstat Next Article
Asciminib monotherapy in Ph+ CML: major molecular responses »
« Patients with lower-risk MDS benefit from imetelstat Next Article
Asciminib monotherapy in Ph+ CML: major molecular responses »
Table of Contents: EHA 2020
Featured articles
Myeloid
VIALE-A: newly diagnosed chemo-ineligible AML
DEC10-VEN superior to intensive chemotherapy in high-risk AML
Magrolimab plus azacitidine: good ORR in MDS/AML
Asciminib monotherapy in Ph+ CML: major molecular responses
CML TKI interruption: Swedish registry results
Patients with lower-risk MDS benefit from imetelstat
Better outcomes adding enasidenib to azacitidine in mIDH2-AML
Lymphoid
PET-stratification can omit radiotherapy in early-stage unfavourable Hodgkin lymphoma
Pembrolizumab improves PFS for relapsed/refractory Hodgkin lymphoma
Promising first-in-human trial of epcoritamab in B-NHL
Two trials: acalabrutinib in CLL
Zanubrutinib versus ibrutinib in Waldenström macroglobulinaemia
Deep responses in R/R CLL with venetoclax monotherapy
MRD assessment post-CAR-T predicts ALL allo-HSCT bridging
Plasma Cell Dyscrasias
Daratumumab for light-chain amyloidosis
Isatuximab triplet improves PFS in R/R MM
Initial results from CAR-T cell therapy in MM: KarMMa
Graft-Versus-Host Disease
GRAVITAS-301: improved complete aGVDH response
Ruxolitinib improves steroid-refractory aGVHD across subtypes
Benign Haematology
Paroxysmal nocturnal haemoglobinuria treatment with pegcetacoplan
Mitapivat, a pyruvate kinase-R activator, in SCD is safe with early efficacy results
SCD LentiGlobin gene therapy: new data on VOC and ACS
Paediatric Haematology
Venetoclax + navitoclax promising for R/R ALL or LL
Nivolumab/brentuximab vedotin in R/R HL: good CMR rates
Bench-to-Bedside Science from the Presidential Symposium
Microbiome predicts B-ALL predisposition
Netrin-1 regulates haematopoietic stem cells
Unrecognised role of iron in neutrophil differentiation
Related Articles
September 9, 2020
Magrolimab plus azacitidine: good ORR in MDS/AML
September 9, 2020
Patients with lower-risk MDS benefit from imetelstat
August 28, 2020
Endothelial damage in COVID-19
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com